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A novel glycoprotein, dysadherin, has an anti-cell – cell adhesion function through downregulating E-cadherin. In this study, we
investigated the expressions of dysadherin and E-cadherin in 82 patients with stage II and III colorectal carcinomas to determine the
correlation between the two molecules and the clinicopathologic features of each tumour. Dysadherin was not expressed in normal
colorectal epithelium. Fifty-one per cent of tumours showed dysadherin immunopositivity in over 50% of cancer cells. Thirty-eight per
cent of tumours showed reduced E-cadherin immunopositivity. The increased expression of dysadherin was significantly associated
with lung metastasis (P¼0.003). The increased expression of dysadherin had a significant impact on patient survival (P¼0.0099 and
0.0036, log-rank test for overall and recurrence-free survival rate, respectively). Furthermore, tumour with increased expression of
dysadherin and reduced expression of E-cadherin showed the worst prognosis (P¼0.0043 and 0.0028, log-rank test for overall and
recurrence-free survival rate, respectively). These results suggest that increased dysadherin expression is a significant indicator of poor
prognosis for patients with advanced colorectal carcinoma.
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A significant number of patients with colorectal carcinoma who
undergo apparently curative resection develop local recurrence or
distant metastasis (Rosen et al, 1998). Adjuvant chemotherapy or
radiation therapy is needed after resection for such biologically
aggressive colorectal carcinomas. Therefore, identification of
factors that accurately predict prognosis is essential.
Cell – cell interactions play pivotal roles in the maintenance and
development of normal tissue (Takeichi, 1990). In cancerous
tissues, disintegration of cell – cell interactions and dissemination
of cancer cells lead to invasive and metastatic growth (Hirohashi,
1998). Cadherins are calcium-dependent cell adhesion molecules
that play an essential role in normal growth and development
via mediation of homophilic cell – cell association (Takeichi,
1990). Several studies have reported that decreased function of
E-cadherin is associated with tumour progression in many cancers,
and in particular E-cadherin acts as a suppressor of invasive ability
(Behrens et al, 1989; Vleminckx et al, 1991; Hirohashi, 2000). Many
immunohistochemical studies evaluating E-cadherin expression
in tumour tissues have demonstrated that reduced expression of
E-cadherin is frequently observed in cancer progression (Katagiri
et al, 1995; Lipponen and Eskelinen, 1995; Yonemura et al, 1995;
Tamura et al, 1996; Nakanishi et al, 1997; Umbas et al, 1997;
Bankfalvi et al, 1999; Ghadimi et al, 1999; Gofuku et al, 1999;
Zheng et al, 1999; Kase et al, 2000).
We previously reported a novel cancer-associated cell mem-
brane glycoprotein, dysadherin, composed of 178 amino acids.
Dysadherin is expressed in a wide variety of cancer cells, but only
to a limited number of normal cells such as lymphocytes,
endothelial cells, and basal cells of stratified squamous epithelium.
Dysadherin inactivates E-cadherin function in a post-transcrip-
tional manner and modulates tumour aggressiveness and metas-
tasis (Ino et al, 2002). In this study we focused on the
clinicopathologic significance of dysadherin and E-cadherin
expression in advanced colorectal carcinoma.
MATERIALS AND METHODS
Materials
Eighty-two routinely processed, formalin-fixed, and paraffin wax-
embedded blocks of colorectal carcinoma was obtained from the
National Cancer Center Hospital. All cases were surgically resected
between January 1990 and December 1990 at the National Cancer
Center Hospital, and diagnosed as primary advanced colorectal
carcinoma. The patients included 44 men and 38 women ranging
in age from 37 to 93 years (mean, 62.6 years). The sample selection
was restricted to consecutive cases diagnosed as stages II and III.
All patients had undergone curative resection. None of the patients
received chemotherapy or radiation therapy preoperatively. The
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was diagnosed by serum CEA level, ultrasonography, computed
tomography scan, and angiography.
Thirty-five cases (42.7%) were classified as stage II, and 47 cases
(57.3%) as stage III. Histologically, 52 cases were classified as well-
differentiated adenocarcinoma, 27 cases as moderately differen-
tiated adenocarcinoma, two cases as mucinous carcinoma, one
case as poorly differentiated adenocarcinoma, and one case as
signet-ring cell carcinoma. During the follow-up period, recur-
rence was observed in 10 stage II cases and 17 stage III, and the
recurrence proved fatal in six stage II cases and 10 stage III cases.
Tumour location, tumour differentiation, liver metastasis, lung
metastasis, lymph node metastasis, lymphatic invasion, and vessel
invasion were all classified according to the criteria of the Japanese
Society for Cancer of the Colon and Rectum (1983).
Immunohistochemistry
Immunohistochemical staining was performed on routinely
processed, formalin-fixed, paraffin wax-embedded blocks of
colorectal carcinoma tissues using an avidin–biotin peroxidase
complex method. After deparaffinisation in xylene and rehydration
in ethanol, the sections were heated in citrate buffer (10mM,p H
6.0) at 1201C for 10min for antigen retrieval. Endogenous
peroxidase was blocked with 1% hydrogen peroxide in methanol
for 20min. Then, sections were incubated with anti-dysadherin
antibody (M53, 1:500 dilution), which had been established in our
laboratory and will be described elsewhere, or anti-E-cadherin
antibody (1:200 dilution, Transduction Laboratories, US) at 41C.
The sections were washed with PBS and incubated with biotiny-
lated anti-mouse IgG antibody and avidin–biotin complex (ABC
kit, Vector Laboratories, UK) and visualised using diaminobenzi-
dine tetrahydrochloride. The sections were counterstained with
haematoxylin. As an internal positive control for dysadherin
staining, positive staining of endothelial cells present in the
primary tumour sections was used. As an internal positive control
for E-cadherin staining, positive staining of normal colorectal
epithelial cells adjacent to the tumours was used; staining was
normally seen at cell – cell borders. As a negative control, normal
mouse immunoglobulin of the same class was used instead of the
first antibody.
Evaluation of E-cadherin and dysadherin expression
Two observers (SA and TS), who had no previous knowledge of the
clinical parameters and outcomes for each patient, independently
reviewed the immunohistochemically stained sections; all dis-
crepancies were resolved by joint review of the slides in question.
Expression. of dysadherin was considered positive if tumour
cells were stained as strongly as adjacent endothelial cells. We
assessed dysadherin expression as the percentage of positively
stained tumour cells relative to total tumour cells. When over 50%
of tumour cells were stained for dysadherin, the tumour was
evaluated as ‘positive dysadherin expression’ (Dys (+)). In
contrast, when fewer than 50% of tumour cells were stained for
dysadherin, the tumour was evaluated as ‘negative dysadherin
expression’ (Dys ( )).
Expression of E-cadherin was considered positive if tumour cells
were stained as strongly as normal epithelial cells adjacent to the
tumour, whereas those that stained more weakly than normal
epithelial cells were considered negative. We also assessed E-
cadherin expression as the percentage of positively stained tumour
cells relative to total tumour cells. When over 80% of tumour cells
were positive, the tumour was evaluated as ‘preserved E-cadherin
expression’ (E-cad (+)). Whereas the tumour was evaluated as
‘reduced E-cadherin expression’ (E-cad ( )) when fewer than 80%
of tumour cells were positive.
Statistical analysis
The relation of clinicopathologic characteristics to the number of
immunopositive tumour cells was analysed using the w
2 test and
ANOVA test where appropriate. Deaths from causes other than
colorectal carcinoma were treated as censored cases. Recurrence-
free survival and overall survival were measured from the date of
surgery to the date that the recurrence was confirmed and the end
of follow-up or death, respectively. Overall survival curves were
determined by using the Kaplan – Meier method and were
analysed with the log-rank test. Multivariate survival analysis was
performed with the Cox proportional hazards regression model.
Differences at Po0.05 were regarded as statistically significant.
RESULTS
Expression of dysadherin
Dysadherin-positive staining was observed at the membranes of
cancer cells, lymphocytes, and endothelial cells as previously
reported (Ino et al, 2002). Membranous dysadherin staining was
localised at intercellular borders of cancer cells and was
heterogeneous in tumour nests. No immunoreactivity was seen
in normal colorectal epithelial cells (Figure 1A, C). Preferential
expression was observed in infiltrative tumour cells in some cases
(Figure 1E). The mean percentage of tumour cells that stained
positively for dysadherin was 52.0732.3% (mean7standard
deviation (s.d.); median, 45%). Therefore, we set the cut-off value
for dysadherin immunopositivity at 50%, which made it simple for
observers to categorise each case according to dysadherin
expression. Thirty-nine per cent (32 out of 82) of cases
demonstrated immunopositivity in over 50% of cancer cells.
The correlations between dysadherin expression and various
clinicopathological factors were analysed. Increased dysadherin
expression was significantly correlated with lung metastasis
(P¼0.003). There was no significant correlation between the
increased expression of dysadherin and other clinicopathological
factors such as age, gender, tumour location, maximum diameter
of the tumour, macroscopic type, TNM stage, tumour differentia-
tion, liver metastasis, lymphatic invasion, and vessel invasion
(Table 1).
Expression of E-cadherin
E-cadherin-positive staining was observed at the cell – cell borders
in normal colorectal epithelial cells and in the majority of cancer
cells (Figure 1B, D). Preserved membranous E-cadherin staining,
with an intensity equal to that of the adjacent normal epithelium,
was present in 62.2% (51 out of 82) of cases (Figure 1D). E-
cadherin immunoreactivity was reduced in 37.8% (31 out of 82) of
cases (Figure 1B).
The reduced expression of E-cadherin was correlated only with
lymphatic invasion (P¼0.046). There was no significant correla-
tion between the reduced expression of E-cadherin and age,
gender, tumour location, maximum diameter of the tumour,
macroscopic type, TNM stage, tumour differentiation, liver
metastasis, lung metastasis, and vessel invasion (Table 1).
In this analysis, dysadherin expression (cut-off, 50%) was not
correlated with E-cadherin expression (P¼0.3744) (Table 2).
Prognostic value of dysadherin and E-cadherin expression
Patients with dysadherin immunopositivity in over 50% of tumour
cells survived significantly shorter than those with dysadherin
immunopositivity in fewer than 50% of tumour cells (P¼0.0099.
and 0.0036, log-rank test for overall and recurrence-free survival
rates, respectively; Figure 2 A, B)
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significantly shorter than those with preserved E-cadherin
immunopositivity (P¼0.0196 and 0.0188, log-rank test for overall
and recurrence-free survival rates, respectively; Figure 2C, D).
Patients with combined dysadherin immunopositivity in over
50% of tumour cells and reduced E-cadherin immunopositivity
survived significantly shorter than those with other combinations
of dysadherin and E-cadherin immunopositivity (P¼0.0043 and
0.0028, log-rank test for overall and recurrence-free survival rates,
respectively; Figure 2E, F).
Multivariate analysis using Cox’s proportional hazards model
revealed that dysadherin immunopositivity and E-cadherin
Figure 1 Dysadherin and E-cadherin expression in colorectal cancers demonstrated by immunohistochemistry. (A)–(D) are the adjacent sections of the
same cases. (A) Dysadherin expression was observed in lymphocytes (arrowheads) and endothelial cells (arrows). Membranous dysadherin staining was
localised at intercellular borders of cancer cells and was heterogeneous in tumour nests. No immunoreactivity was seen in normal colorectal epithelial cells
(magnification  200). (B) E-cadherin expression was observed at the cell–cell borders in normal epithelial cells, and was reduced in the majority of cancer
cells in this section (magnification  200). (C) Tumour cells were positively stained for dysadherin (magnification  200). (D) E-cadherin expression was
not reduced in tumour cells where dysadherin was expressed (magnification  200). (E) Preferential dysadherin expression was observed in infiltrative
tumour cells (arrow) in some cases (magnification  200).
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factors when adjusted for age, gender, maximum tumour diameter,
tumour differentiation, lymph node metastasis, lymphatic inva-
sion, and vessel invasion (Table 3).
DISCUSSION
We reported previously that dysadherin has an anti-cell – cell
adhesion function and downregulates E-cadherin, on the basis of
the observation that introduction of dysadherin induced decreased
the protein expression and function of E-cadherin without
affecting its transcription (Ino et al, 2002). In various cancerous
tissues, a reduced expression of E-cadherin has frequently been
observed in cancer progression (Katagiri et al, 1995; Lipponen and
Eskelinen, 1995; Yonemura et al, 1995; Tamura et al, 1996;
Nakanishi et al, 1997; Umbas et al, 1997; Bankfalvi et al, 1999;
Ghadimi et al, 1999; Zheng et al, 1999; Kase et al, 2000; Gofuku
et al, 1999). The aim of this study was to verify immunohisto-
chemically the hypothesis that dysadherin, which suppresses the
E-cadherin system, might play a significant role in the aggressive-
ness of colorectal carcinoma.
As in our previous study (Ino et al, 2002), we confirmed that
dysadherin was expressed heterogeneously in tumour nests, in that
it was expressed in dissociating cells or infiltrative tumour nests
and also in parts of well-differentiated tumour nests. As reported,
dysadherin was not detected in normal colorectal epithelium, but
was expressed significantly in endothelial cells. Use of these cells as
internal controls allowed easy assessment of dysadherin expression
by cancer cells.
The metastatic process involves a complex series of events that
must include changes in the status of adhesion molecules of the
tumour cells. E-cadherin, which is responsible for calcium-
dependent homophilic interaction between epithelial cells, has
been shown to be downregulated in several tumours including
colorectal carcinoma (Ghadimi et al, 1999; Gofuku et al, 1999).
Several mechanisms have been proposed for the inactivation of the
cadherin/catenin complex in tumour cells, such as mutations in
the genes for E-cadherin, a-catenin, and b-catenin (Hirano et al,
Table 1 Correlation between expression of E-cadherin and dysadherin and clinicopathological characteristics in patients with advanced colorectal
carcinoma (stages II and III)
E-cadherin Dysadherin
Variables Preserved Reduced P-value Fewer than 50% Over 50% P-value
Age (mean7s.d.)(years) 62.3710.9 62.0710.8 0.784 62.2711.6 63.0710.4 0.746
Gender
Male 31 13 24 20
Female 20 18 0.097 26 12 0.199
Tumour location
Colon 24 16 27 13
Rectum 27 15 0.689 23 19 0.237
Maximum diameter of the tumour
Mean7s.d. (cm) 5.2172.23 5.4772.31 0.767 5.6772.15 5.0872.34 0.247
Macroscopic type
a
12 4 3 3
24 3 2 3 4 1 2 5
35 4 5 4
4 1 0 0.369 1 0 0.779
TNM stage
II 22 13 23 12
III 29 18 0.915 27 20 0.448
Tumour Differentiation
b
Well 32 19 33 18
Mod, por, sig, muci 19 12 0.895 17 14 0.376
Liver metastasis
Positive 5 8 7 6
Negative 46 23 0.054 43 26 0.566
Lung metastasis
Positive 6 2 1 7
Negative 45 29 0.431 49 25 0.003
Lymphatic invasion
Positive 23 21 37 26
Negative 28 10 0.046 13 6 0.448
Vessel invasion
Positive 14 6 11 9
Negative 37 25 0.408 39 23 0.529
aCorresponding to Borrman’s classification: 1=polypoid; 2=ulcerated circumscribed; 3=ulcerated infiltrative; 4=diffusely infiltrative.
bWell=well-differentiated adenocarcinoma; mod=moderately differentiated adenocarcinoma; poor=poorly differentiated adenocarcinoma; sig=signet-ring cell carcinoma;
muci=mucinous carcinoma.
Table 2 Cases classified by dysadherin expression and E-cadherin
expression
Dysadherin expression
E-cadherin expression Fewer than 50% Over 50%
Preserved 33 18
Reduced 17 14
P=0.3744.
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hypermethylation around the promoter region of the E-cadherin
gene (Yoshiura et al, 1995), and aberrant tyrosine phosphorylation
of b-catenin (Behrens et al, 1993). In this study, reduced
E-cadherin expression was observed in 37.8% (31 out of 82) of
tumours, which was less than reported previously (Dorudi et al,
1995; Mohri, 1997; Ikeguchi et al, 2000). This discrepancy may be a
result of the different evaluation system for immunopositivity or of
the different cases examined; we restricted sample selection to
consecutive cases diagnosed as stages II and III. However, as in
previous studies (Dorudi et al, 1995; Mohri, 1997; Ikeguchi et al,
2000), the present immunohistochemical data demonstrate that
reduced E-cadherin expression is significantly correlated with poor
survival.
Figure 2 Overall survival (A) and recurrence-free survival (B) of patients in relation to dysadherin expression (log-rank test for trend: P¼0.010, 0.004,
respectively). Overall survival (C) and recurrence-free survival (D) of patients in relation to E-cadherin expression (log-rank test for trend: P¼0.020, 0.020,
respectively). Overall survival (E) and recurrence-free survival (F) of patients in relation to the combination of dysadherin and E-cadherin expression (log-
rank test for trend: P¼0.004, 0.003, respectively). Dys (+), dysadherin expression in over 50% of tumour cells; Dys ( ), dysadherin expression in fewer than
50% of tumour cells; E-cad (+), E-cadherin expression in over 80% of tumour cells; E-cad ( ), E-cadherin expression in fewer than 80% of tumour cells.
Table 3 Multivariate Cox’s proportional hazard analysis
Overall survival Recurrence-free survival
Prognostic factors HR 95% CI P-value HR 95% CI P-value
Dysadherin 3.497 1.032–11.851 0.0444 2.522 1.064–5.977 0.0356
E-cadherin 3.588 1.075–11.982 0.0378 2.393 1.013–5.653 0.0466
Gender 0.957 0.957–0.264 0.9468 0.91 0.363–2.282 0.8412
Age 3.751 0.533–26.372 0.184 1.339 0.372–4.822 0.6554
Maximum diameter of the tumour 1.729 0.379–7.886 0.4793 1.164 0.408–3.324 0.7765
Tumour differentiation (well vs others) 2.116 0.612–7.323 0.2366 1.2 0.479–3.009 0.6972
Lymphatic invasion 1.143 0.247–5.281 0.864 1.406 0.450–4.388 0.5578
Vessel invasion 1.601 0.379–6.767 0.5219 1.262 0.449–3.546 0.6592
Lymph node metastasis 1.213 0.367–4.013 0.7516 1.538 0.639–3.702 0.3369
HR=hazard ratio; CI=confidence interval.
Dysadherin expression in colorectal cancer
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post-transcriptional downregulation of E-cadherin (Ino et al,
2002). In this immunohistochemical study, although dysadherin
was detected in part of some tumours, where E-cadherin
expression was decreased, positive dysadherin expression was
not correlated with reduced E-cadherin expression. This result
suggests that mechanisms may exist for the reduction of E-
cadherin expression other than that related to dysadherin
expression. Our immunohistochemical data also demonstrate that
increased dysadherin expression is significantly correlated with
poor survival. Furthermore, tumours with both increased expres-
sion of dysadherin and reduced expression of E-cadherin showed
the worst prognosis, and tumours with the opposite combination
of the two molecules showed the best prognosis. These results
suggest that dysadherin expression might be an excellent indicator
of the patients with advanced colorectal carcinoma and the
combined immunohistochemical analysis of dysadherin and E-
cadherin expression could give us further prognostic information.
In the current study we categorised patients simply into two
groups setting the cut-off value for dysadherin immunopositivity
at 50%, on the ground that the mean percentage of dysadherin-
positive tumour cells was 52.0732.3% (mean7s.d.; median, 45%).
We also confirmed the prognostic importance of dysadherin
positivity by classifying dysadherin expression into four categories
(0–10, 10–30, 30–50, more than 50% positivity) (data not shown).
Although curative resection of advanced colorectal carcinoma
without synchronous distant metastasis (ie stage II or III) is
feasible, a significant number of patients develop local recurrence
or distant metastasis heterochronously (Newland et al, 1995; Rosen
et al, 1998). Liver metastasis is an important prognostic
determinant for the clinical prognosis of colorectal carcinoma
(Doci et al, 1991; Wanebo et al, 1996; Rees et al, 1997). Therefore, a
prognostic indicator correlated with liver metastasis and that can
be assessed at the time of resection of the primary tumour is
required to aid in the selection of patients for adjuvant therapy.
Tumour suppressor genes such as nm23 (Yamaguchi et al, 1993),
DCC (Saito et al, 1999) and Smad4 (Miyaki et al, 1999) have been
reported to play a role in liver metastasis. As for adhesion mole-
cules, reduction of the E-cadherin–catenin system (Hirohashi,
1998) and expression of variant CD44 (Wielenga et al, 1993) have
been studied as biological markers of liver metastasis. In the
previous study (Ino et al, 2002), we demonstrated that dysadherin
promoted the metastatic activity by in vivo metastasis assay.
In this study positive dysadherin expression was observed in six
of 13 cases, which developed liver metastasis postoperatively.
Considering that various mechanisms may be involved in liver
metastasis and stage IV colorectal carcinoma, including synchro-
nous liver metastasis, were out of subject in our current study,
further analysis will be required to examine the relation between
dysadherin expression and liver metastasis.
Interestingly, positive dysadherin expression was observed in
seven of eight cases which developed lung metastasis hetero-
chronously. In three out of those eight cases, the metastatic lesions
were surgically resected. Immunohistochemically, dysadherin was
expressed heterogeneously in all three lung metastatic lesions
as much as in the corresponding primary tumours (data not
shown). Although the process of lung metastasis of colorectal
carcinoma is still unclear, dysadherin might present a predictive
information at the time of the resection of primary lesion.
In conclusion, we have demonstrated a significant correlation
between the expression of dysadherin and the prognosis of
patients with advanced colorectal carcinoma. Univariate and
multivariate analyses revealed that the expression of dysadherin
in tumour cells might be an excellent and independent prognostic
indicator for patients with advanced colorectal carcinoma.
ACKNOWLEDGEMENTS
We thank Ms Y Yamauchi for her expert technical assistance. S
Aoki and T Shimamura contributed equally to this work. S Aoki
and T Shimamura are Awardees of a Research Resident Fellowship
from the Foundation for Promotion of Cancer Research in Japan.
This research was supported in part by a Grant-in-Aid for the
Second Term Comprehensive 10-Year Strategy for Cancer Control
from the Ministry of Health and Welfare, Japan, and by a Grant-in-
Aid for Scientific Research (A) from the Ministry of Education,
Science, Sports and Culture.
REFERENCES
Bankfalvi A, Terpe HJ, Breukelmann D, Bier B, Rempe D, Pschadka G
et al (1999) Immunophenotypic and prognostic analysis of E-cadherin
and beta-catenin expression during breast carcinogenesis and
tumour progression: a comparative study with CD44. Histopathology
34: 25–34
Behrens J, Mareel MM, Van Roy FM, Birchmeier W (1989) Dissecting
tumour cell invasion: epithelial cells acquire invasive properties after
the loss of uvomorulin-mediated cell – cell adhesion. J Cell Biol 108:
2435–2447
Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM et al
(1993) Loss of epithelial differentiation and gain of invasiveness
correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin
complex in cells transformed with a temperature-sensitive v-SRC gene. J
Cell Biol 120: 757–766
Doci R, Gennari L, Bignami P, Montalto F, Morabito A, Bozzetti F (1991)
One hundred patients with hepatic metastases from colorectal cancer
treated by resection: analysis of prognostic determinants. Br J Surg 78:
797–801
Dorudi S, Hanby AM, Poulsom R, Northover J, Hart IR (1995) Level of
expression of E-cadherin mRNA in colorectal cancer correlates with
clinical outcome. Br J Cancer 71: 614–616
Ghadimi BM, Behrens J, Hoffmann I, Haensch W, Birchmeier W, Schlag PM
(1999) Immunohistological analysis of E-cadherin, alpha-, beta- and
gamma-catenin expression in colorectal cancer: implications for cell
adhesion and signaling. Eur J Cancer 35: 60–65
Gofuku J, Shiozaki H, Tsujinaka T, Inoue M, Tamura S, Doki Y et al (1999)
Expression of E-cadherin and alpha-catenin in patients with colorectal
carcinoma. Correlation with cancer invasion and metastasis. Am J Clin
Pathol 111: 29–37
Hirano S, Kimoto N, Shimoyama Y, Hirohashi S, Takeichi M (1992)
Identification of a neural alpha-catenin as a key regulator of cadherin
function and multicellular organization. Cell 70: 293–301
Hirohashi S (1998) Inactivation of the E-cadherin-mediated cell adhesion
system in human cancers. Am J Pathol 153: 333–339
Hirohashi S (2000) Molecular aspects of adhesion–epigenetic mechanisms
for inactivation of the E-cadherin-mediated cell adhesion system in
cancers. Verh Dtsch Ges Pathol 84: 28–32
Ikeguchi M, Taniguchi T, Makino M, Kaibara N (2000) Reduced E-cadherin
expression and enlargement of cancer nuclei strongly correlate with
hematogenic metastasis in colorectal adenocarcinoma. Scand J Gastro-
enterol 35: 839–846
Ino Y, Gotoh M, Sakamoto M, Tsukagoshi K, Hirohashi S (2002)
Dysadherin, a cancer-associated cell membrane glycoprotein, down-
regulates E-cadherin and promotes metastasis. Proc Natl Acad Sci USA
99: 365–370
Japanese Research Society for Cancer of the Colon and Rectum (1983)
General rules for clinical and pathological studies on cancer of the colon,
rectum and anus. Part I. Clinical classification. Jpn J Surg 13: 557–573
Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K (2000)
Expression of E-cadherin and beta-catenin in human non-small cell lung
cancer and the clinical significance. Clin Cancer Res 6: 4789–4796
Katagiri A, Watanabe R, Tomita Y (1995) E-cadherin expression in renal
cell cancer and its significance in metastasis and survival. Br J Cancer 71:
376–379
Dysadherin expression in colorectal cancer
S Aoki et al
731
British Journal of Cancer (2003) 88(5), 726–732 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yLipponen PK, Eskelinen MJ (1995) Reduced expression of E-cadherin
is related to invasive disease and frequent recurrence in bladder cancer.
J Cancer Res Clin Oncol 121: 303–308
Machado JC, Soares P, Carneiro F, Rocha A, Beck S, Blin N et al (1999)
E-cadherin gene mutations provide a genetic basis for the phenotypic
divergence of mixed gastric carcinomas. Lab Invest 79: 459–465
Miyaki M, Iijima T, Konishi M, Sakai K, Ishii A, Yasuno M et al (1999)
Higher frequency of Smad4 gene mutation in human colorectal cancer
with distant metastasis. Oncogene 18: 3098–3103
Mohri Y (1997) Prognostic significance of E-cadherin expression in human
colorectal cancer tissue. Surg Today 27: 606–612
Nakanishi Y, Ochiai A, Akimoto S, Kato H, Watanabe H, Tachimori Y et al
(1997) Expression of E-cadherin, alpha-catenin, beta-catenin and
plakoglobin in esophageal carcinomas and its prognostic significance:
immunohistochemical analysis of 96 lesions. Oncology 54: 158–165
Newland RC, Dent OF, Chapuis PH, Bokey L (1995) Survival after curative
resection of lymph node negative colorectal carcinoma. A prospective
study of 910 patients. Cancer 76: 564–571
Oda T, Kanai Y, Oyama T, Yoshiura K, Shimoyama Y, Birchmeier W et al
(1994) E-cadherin gene mutations in human gastric carcinoma cell lines.
Proc Natl Acad Sci USA 91: 1858–1862
Oyama T, Kanai Y, Ochiai A, Akimoto S, Oda T, Yanagihara K et al (1994)
A truncated beta-catenin disrupts the interaction between E-cadherin
and alpha-catenin: a cause of loss of intercellular adhesiveness in human
cancer cell lines. Cancer Res 54: 6282–6287
Rees M, Plant G, Bygrave S (1997) Late results justify resection for multiple
hepatic metastases from colorectal cancer. Br J Surg 84: 1136–1140
Rosen M, Chan L, Beart Jr RW, Vukasin P, Anthone G (1998) Follow-up of
colorectal cancer: a meta-analysis. Dis Colon Rectum 41: 1116–1126
Saito M, Yamaguchi A, Goi T, Tsuchiyama T, Nakagawara G, Urano T et al
(1999) Expression of DCC protein in colorectal tumours and its
relationship to tumour progression and metastasis. Oncology 56: 134–141
Takeichi M (1990) Cadherins: a molecular family important in selective cell
– cell adhesion. Annu Rev Biochem 59: 237–252
Tamura S, Shiozaki H, Miyata M, Kadowaki T, Inoue M, Matsui S et al
(1996) Decreased E-cadherin expression is associated with haematogen-
ous recurrence and poor prognosis in patients with squamous cell
carcinoma of the oesophagus. Br J Surg 83: 1608–1614
Umbas R, Isaacs WB, Bringuier PP, Xue Y, Debruyne FM, Schalken JA
(1997) Relation between aberrant alpha-catenin expression and loss of
E-cadherin function in prostate cancer. Int J Cancer 74: 374–377
Vleminckx K, Vakaet Jr L, Mareel M, Fiers W, van Roy F (1991) Genetic
manipulation of E-cadherin expression by epithelial tumour cells reveals
an invasion suppressor role. Cell 66: 107–119
Wanebo HJ, Chu QD, Avradopoulos KA, Vezeridis MP (1996) Current
perspectives on repeat hepatic resection for colorectal carcinoma: a
review. Surgery 119: 361–371
Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM,
Ponta H et al (1993) Expression of CD44 variant proteins in human
colorectal cancer is related to tumour progression. Cancer Res 53:
4754–4756
Yamaguchi A, Urano T, Fushida S, Furukawa K, Nishimura G, Yonemura Y
et al (1993) Inverse association of nm23-H1 expression by colorectal
cancer with liver metastasis. Br J Cancer 68: 1020–1024
Yonemura Y, Nojima N, Kaji M, Fujimura T, Itoh H, Ninomiya I et al
(1995) E-cadherin and urokinase-type plasminogen activator tissue
status in gastric carcinoma. Cancer 76: 941–953
Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S
(1995) Silencing of the E-cadherin invasion-suppressor gene by CpG
methylation in human carcinomas. Proc Natl Acad Sci USA 92: 7416–7419
Zheng Z, Pan J, Chu B, Wong YC, Cheung AL, Tsao SW (1999)
Downregulation and abnormal expression of E-cadherin and beta-catenin
in nasopharyngeal carcinoma: close association with advanced disease
stage and lymph node metastasis. Hum Pathol 30: 458–466
Dysadherin expression in colorectal cancer
S Aoki et al
732
British Journal of Cancer (2003) 88(5), 726–732 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y